サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1375994

アトピー性皮膚炎治療薬の市場規模、シェア、動向分析レポート：薬剤クラス別、投与経路別、地域別、セグメント別予測、2023年～2030年

Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Route Of Administration, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
アトピー性皮膚炎治療薬の市場規模、シェア、動向分析レポート：薬剤クラス別、投与経路別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年10月23日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アトピー性皮膚炎治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、アトピー性皮膚炎治療薬の世界市場規模は2030年までに276億8,000万米ドルに達する見込みです。

2023年から2030年までのCAGRは8.4%で拡大する見込みです。アトピー性皮膚炎 (AD) 治療薬市場は、世界のアトピー性皮膚炎の有病率の増加、認知度の向上、治療需要の高さなどの要因により、成長機会が見込まれています。さらに、市場を獲得するための革新的な製品の継続的な発売は、市場シェアを獲得し優位性を維持するためにプレーヤーが採用する主要な戦略です。

有効性が高く副作用の少ないパイプラインの製品数が増加していることが、市場を牽引すると予想されます。例えば、アトピー性皮膚炎を適応症とする新薬は、2020年から2029年にかけて11品目が上市されると予測されています。これらには以下の薬剤クラス別が含まれる：ヤヌスキナーゼ (JAK) 阻害剤、ホスホジエステラーゼ-4 (PDE-4)、インターロイキン-4&-13 (IL-4/13) などです。これらの新薬の上市は、重度および中等度のAD患者にQOLの改善と治療の選択肢を提供するものです。

ファスト・トラック指定などの規制当局からの支援は、ADの研究開発を促進すると予想されます。例えば、デミラ社のレブリキズマブはファストトラック指定を受けた。さらに、2020年10月には、Forte Biosciences, Inc.の医薬品FB-401がFDAからファストトラック指定を受けた。したがって、研究開発に対する企業の関心の高まりが市場の成長を促進すると予想されます。

アトピー性皮膚炎の新規治療法の研究開発に対する資金提供の増加と政府の積極的な取り組みが、この地域の成長を後押しすると思われます。公的団体と民間団体の協力により、世界中で消費者の認識が高まると予想されます。例えば、2022年6月、大塚製薬株式会社 (大塚ホールディングス株式会社) は、AD治療薬モイゼルト軟膏 (ジファミラスト) の日本での発売を発表しました。本剤は、非ステロイド系の外用ホスホジエステラーゼ4型阻害剤です。

日本では日本皮膚科学会 (JDA) がADガイドラインを定めています。このガイドラインは2020年に改訂され、診断基準だけでなく治療法も明記されました。例えば、炎症に関連したADは、副腎皮質ステロイド外用薬とタクロリムスを用いて治療されます。これにより、患者に対する体系的な治療が容易になり、治療効果が向上します。

アトピー性皮膚炎治療薬市場のハイライト

  • 2022年のアトピー性皮膚炎治療薬市場は、生物学的製剤の需要の高まりと承認件数の増加により、生物学的製剤が優位を占めました。
  • 2022年には注射剤投与経路が最大のシェアを占め、予測期間を通じてその優位性を維持するとみられます。
  • 北米は、大手企業の存在、アトピー性皮膚炎の有病率の増加、同地域内での研究活動の活発化により、2022年の市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 アトピー性皮膚炎治療薬市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • アトピー性皮膚炎治療薬市場の分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 アトピー性皮膚炎治療薬：薬剤クラス別の推定・動向分析

  • アトピー性皮膚炎治療薬市場：重要なポイント
  • アトピー性皮膚炎治療薬市場：動向と市場シェア分析、2022年および2030年
  • コルチコステロイド
    • コルチコステロイド市場推計・予測、2018年から2030年まで
  • カルシニューリン阻害剤
    • カルシニューリン阻害剤市場推計・予測、2018年から2030年まで
  • PDE4阻害剤
    • PDE4阻害剤市場推計・予測、2018年から2030年まで
  • 生物製剤
    • 生物製剤市場推計・予測、2018年から2030年まで
  • その他
    • その他の市場推計・予測、2018年から2030年まで

第5章 アトピー性皮膚炎治療薬：投与経路別の推定・動向分析

  • アトピー性皮膚炎治療薬市場：重要なポイント
  • アトピー性皮膚炎治療薬市場：動向と市場シェア分析、2022年および2030年
  • 局所薬
  • 注射薬
  • 経口薬

第6章 アトピー性皮膚炎治療薬市場：地域別の推定・動向分析

  • 地域別の展望
  • 地域別のアトピー性皮膚炎治療薬市場：主要市場のポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Pfizer Inc.
    • Sanofi
    • Regeneron Pharmaceuticals Inc.
    • LEO Pharma Inc
    • Otsuka Pharmaceutical Co., Ltd.
    • AbbVie Inc.
    • GALDERMA LABORATORIES, L.P.
    • Dermira, Inc. (Eli Lilly and Company)
    • Novartis AG
    • Incyte Corporation
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 North America atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 4 North America atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 U.S. atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 7 Canada atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 Canada atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9 Europe atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 Europe atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 Europe atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Germany atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 UK atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 UK atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16 France atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 France atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Italy atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 Italy atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 20 Spain atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Spain atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 Sweden atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 Sweden atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 Norway atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Norway atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 26 Denmark atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Denmark atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 China atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 China atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33 Japan atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Japan atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 India atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 India atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 Thailand atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Thailand atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 South Korea atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 South Korea atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41 Latin America atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Latin America atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Latin America atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 44 Brazil atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 45 Brazil atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 46 Mexico atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 Mexico atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 Argentina atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 49 Argentina atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 50 Middle East and Africa atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Middle East and Africa atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 53 South Africa atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 South Africa atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 Saudi Arabia atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57 UAE atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 UAE atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59 Kuwait atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 Kuwait atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Atopic dermatitis drugs: Market outlook
  • Fig. 9 Atopic dermatitis drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Atopic dermatitis drugs market driver impact
  • Fig. 15 Atopic dermatitis drugs market restraint impact
  • Fig. 16 Atopic dermatitis drugs market strategic initiatives analysis
  • Fig. 17 Atopic dermatitis drugs market: Drug class movement analysis
  • Fig. 18 Atopic dermatitis drugs market: Drug class outlook and key takeaways
  • Fig. 19 Corticosteroids market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Calcineurin inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 PDE4 inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Biologics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Atopic dermatitis drugs market: Route of administration movement analysis
  • Fig. 25 Atopic dermatitis drugs market: Route of administration outlook and key takeaways
  • Fig. 26 Topical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Injectable market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Oral market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Global atopic dermatitis drugs market: Regional movement analysis
  • Fig. 30 Global atopic dermatitis drugs market: Regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-2-68038-546-5

Atopic Dermatitis Drugs Market Growth & Trends:

The global atopic dermatitis drugs market size is expected to reach USD 27.68 billion by 2030, according to a new report by Grand View Research, Inc.. It is expected to expand at a CAGR of 8.4% from 2023 to 2030. The market for atopic dermatitis (AD) drugs is expected to witness growth opportunities owing to factors such as the increasing prevalence of atopic dermatitis across the globe, rising awareness, and high demand for treatment. Furthermore, the ongoing launch of innovative products to capture the market is a key strategy adopted by the players to gain market share and maintain their dominance.

A rising number of products in the pipeline, which are highly effective and show fewer adverse effects, is expected to drive the market. For instance, overall, 11 novel drugs indicated for atopic dermatitis are anticipated to be launched in the global market between 2020 and 2029. These include the following drug classes: Janus Kinase (JAK) inhibitors, phosphodiesterase-4 (PDE-4), and interleukin-4 & -13 (IL-4/13). These launches offer improvement in the quality of life and additional choices of treatments to patients with severe and moderate forms of AD.

Support from regulatory authorities, such as the provision of fast-track designation, is anticipated to impel R&D on AD. For instance, Lebrikizumab by Demira, Inc. received a fast-track designation. Moreover, in October 2020, Forte Biosciences, Inc.'s drug FB-401 was granted the fast-track designation by the FDA. Hence, the growing interest of companies in R&D is expected to propel the growth of the market.

An increase in funding for research and development of novel therapies for atopic dermatitis combined with proactive government initiatives will boost regional growth. Collaborations between public and private associations are expected to increase consumer awareness across the globe. For instance, in June 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.) announced the launch of Moizerto ointment (difamilast) for treating AD in Japan. This ointment is a non-steroidal topical phosphodiesterase type-4 inhibitor.

The Japanese Dermatological Association (JDA) provides AD guidelines for AD in Japan. These guidelines were revised in 2020, specifying diagnostic criteria as well as treatments. For instance, inflammation-related AD is treated using topical corticosteroids and tacrolimus. This facilitates the treatment of patients in a systematic manner, thus improving treatment efficacy.

Atopic Dermatitis Drugs Market Report Highlights:

  • In 2022, biologics dominated the market owing to their higher demand and rising biologics approvals
  • The injectable route of administration segment held the largest share in 2022 and is likely to maintain its dominance throughout the forecast period
  • North America dominated the market in 2022 due to the presence of leading market players, increased prevalence of atopic dermatitis, and increased research activities within the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Class
    • 1.1.2. Route of Administration
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Route of administration outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Atopic Dermatitis Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Atopic Dermatitis Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Atopic Dermatitis Drugs: Drug Class Estimates & Trend Analysis

  • 4.1. Atopic Dermatitis Drugs Market: Key Takeaways
  • 4.2. Atopic Dermatitis Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Corticosteroids
    • 4.3.1. Corticosteroids market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Calcineurin Inhibitors
    • 4.4.1. Calcineurin inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. PDE4 Inhibitors
    • 4.5.1. PDE4 Inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Biologics
    • 4.6.1. Biologics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Atopic Dermatitis Drugs: Route of Administration Estimates & Trend Analysis

  • 5.1. Atopic Dermatitis Drugs Market: Key Takeaways
  • 5.2. Atopic Dermatitis Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Topical
    • 5.3.1. Topical market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Injectable
    • 5.4.1. Injectable market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Oral
    • 5.5.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Atopic Dermatitis Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Atopic Dermatitis Drugs Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Pfizer Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Sanofi
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Regeneron Pharmaceuticals Inc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. LEO Pharma Inc
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Otsuka Pharmaceutical Co., Ltd.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. AbbVie Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. GALDERMA LABORATORIES, L.P.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Dermira, Inc. (Eli Lilly and Company)
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Novartis AG
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Incyte Corporation
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives